In the wake of the controversial U.S. regulatory approval of the Alzheimer’s drug aducanumab, physicians count on many sufferers with reminiscence issues will need to know whether or not they’re eligible. But a definitive prognosis is pricey and time-consuming, involving a hunt for indicators of illness, or biomarkers, in sufferers’ spinal fluid or in positron emission tomography scans. The demand threatens to overwhelm the well being system. An innovation may assist handle the deluge: easy blood tests for molecules that will point out indicators of illness within the mind. With a number of promising tests below improvement, corporations at the moment are working to make them match for widespread medical use—and docs are scrambling to resolve when and methods to use them.